Kerri Fitzgerald

Articles by Kerri Fitzgerald

Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Kerri FitzgeraldMantle Cell Lymphoma | December 13, 2023
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK.
Kerri FitzgeraldMantle Cell Lymphoma | December 15, 2023
Study authors noted that the findings underscore the need for tailored approaches to MRD testing.
Kerri FitzgeraldAggressive B-Cell Lymphoma | September 30, 2024
The FDA approves the first bispecific antibody for relapsed/refractory DLBCL.
Kerri FitzgeraldMantle Cell Lymphoma | February 1, 2023
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Kerri FitzgeraldMeeting News | December 21, 2022
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
Kerri FitzgeraldMeeting News | December 21, 2022
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Kerri FitzgeraldMeeting News | February 3, 2023
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Kerri FitzgeraldMeeting News | February 1, 2023
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
Kerri FitzgeraldAcute Myeloid Leukemia | February 1, 2023
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Kerri FitzgeraldMeeting News | February 1, 2023
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
Kerri FitzgeraldHodgkin Lymphoma | December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Kerri FitzgeraldMyelofibrosis | April 12, 2023
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Kerri FitzgeraldMyeloma | December 10, 2022
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
Kerri FitzgeraldMyeloproliferative Neoplasms | May 30, 2023
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Kerri FitzgeraldMyelofibrosis | April 12, 2023
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | December 10, 2022
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
Kerri FitzgeraldAcute Myeloid Leukemia | December 8, 2022
Venetoclax plus HMAs led to higher response rates than non-venetoclax regimens in patients with newly diagnosed AML.
Leah SherwoodPrint | November 28, 2022
Courtney D. DiNardo, MD, MSCE, talks about mentorship and her research on hereditary cancer predisposition syndromes.